Angiodynamics Inc. logo

Angiodynamics Inc. (ANGO)

Market Closed
25 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
9. 22
+0.11
+1.21%
$
365.06M Market Cap
- P/E Ratio
0% Div Yield
410,997 Volume
-0.39 Eps
$ 9.11
Previous Close
Day Range
9.03 9.29
Year Range
5.83 13.5
Want to track ANGO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 66 days
AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-digit EBITDA margins in time. Clinical data for AlphaVac and NanoKnife were positive relative to established standards of care, suggesting potentially competitive offerings in the pulmonary embolism and prostate cancer markets if management can execute. Auryon, AlphaVac, and NanoKnife all offer double-digit growth potential, but sales execution against larger entrenched rivals is not going to be easy and the Med Device business offers limited potential.

Seekingalpha | 6 months ago
AngioDynamics price target raised to $15 from $12 at Canaccord

AngioDynamics price target raised to $15 from $12 at Canaccord

Canaccord raised the firm's price target on AngioDynamics to $15 from $12 and keeps a Buy rating on the shares. AngioDynamics reported one of its strongest quarters in recent memory, the analyst tells investors in a research note. The firm back-end loaded its NanoKnife expectations for this fiscal year, but thinks in the long-term it could provide significant growth for AngioDynamics. It sees thrombectomy acceleration today with improving profitability.

Thefly | 6 months ago
AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines

AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines

ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business.

Zacks | 6 months ago
AngioDynamics: A Surgical Approach To Market Growth

AngioDynamics: A Surgical Approach To Market Growth

AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and key products like Auryon, AlphaVac, and AngioVac showing strong performance and market acceptance. NanoKnife's FDA clearance and promising clinical trials highlight its potential in prostate cancer treatment, contributing to a 23.1% rise in disposable revenue.

Seekingalpha | 6 months ago
AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

AngioDynamics, Inc. (NASDAQ:ANGO ) Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Stephen Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics Fiscal Year 2025 Second Quarter Earnings Call.

Seekingalpha | 6 months ago
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates

AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates

AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago.

Zacks | 6 months ago
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife

ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife

AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.

Zacks | 7 months ago
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?

Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?

AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 7 months ago
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade

The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 8 months ago
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?

AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?

ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.

Zacks | 9 months ago
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE

ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE

AngioDynamics announces the receipt of CPT Category I code for IRE technology.

Zacks | 9 months ago
AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks | 9 months ago
Loading...
Load More